Overview

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran ODT under fasting conditions in healthy, non-smoking adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Ondansetron